Physician-scientist and global HIV strategist will contribute to scientific discussions on innovation, implementation, and equitable access at the International AIDS Society Conference.

RIO DE JANEIRO, BRAZIL / ACCESS Newswire / July 27, 2026 / Dr. Max Lataillade, a physician-scientist and global HIV strategist at the Gates Foundation, will participate in four scientific sessions during the 2026 International AIDS Society (IAS) Conference in Rio de Janeiro, Brazil, contributing to discussions on the advancement of long-acting HIV prevention and treatment.

The annual IAS Conference brings together researchers, clinicians, policymakers, and community leaders from around the world to share the latest scientific developments and strategies for addressing the global HIV epidemic.

At the Gates Foundation, Dr. Lataillade leads HIV drug development and strategy, collaborating with researchers, biotechnology innovators, product development partnerships, governments, and community organizations to advance the development of next-generation HIV medicines. His work focuses on supporting innovations designed to improve treatment and prevention options while expanding equitable access worldwide.

Dr. Lataillade will participate in the following conference sessions:

• "Opportunities and Challenges with the ARV Innovation Pile-Up," Prevention Summit (R4P) pre-conference, July 26, 9:30 AM.

• "From Strategy to Execution: Delivering the Next Generation of Long-Acting HIV Drugs for Prevention, PEP and Treatment for LMICs," HIV Post-Exposure Prophylaxis Summit, July 27, 9:30 AM.

• "Long-Acting Antiretrovirals: A Transformational Path to Ending the HIV Epidemic in LMIC," AVAC Satellite Symposium, "Shared Pipeline; Shared Goal," July 27, 11:30 AM.

• "Bringing Together Community, Research and Advocacy to Move Prevention Forward," session on translating science into sustainable action, July 28, 4:30 PM.

The sessions will explore scientific advances in long-acting HIV therapies, implementation strategies, collaboration across sectors, and approaches to expanding access to emerging prevention and treatment options.

"Long-acting HIV medicines have the potential to expand prevention and treatment options for people around the world," said Dr. Lataillade. "Meetings like IAS provide an opportunity for researchers, clinicians, public health leaders, and communities to exchange knowledge and work together on the scientific and implementation challenges that remain."

Before joining the Gates Foundation, Dr. Lataillade held scientific and leadership roles at ViiV Healthcare and Bristol Myers Squibb, where he contributed to the development of several HIV therapies, including fostemsavir (Rukobia®), the first HIV attachment inhibitor approved for heavily treatment-experienced people living with HIV.

Throughout his career, Dr. Lataillade has worked across clinical medicine, pharmaceutical research and development, biotechnology, and global health, with a focus on advancing innovative therapies for people living with or at risk for HIV.

For more information, visit linkedin.com/in/maxlataillade.

About Dr. Max Lataillade

Dr. Max Lataillade is a physician, infectious disease specialist, drug developer, and global health strategist. At the Gates Foundation, he leads HIV drug development and strategy to help accelerate the development of innovative HIV prevention and treatment options through scientific collaboration and global partnerships. He previously held leadership positions at ViiV Healthcare and Bristol Myers Squibb and has authored more than 45 peer-reviewed scientific publications. He also serves as an Assistant Professor of Medicine at Yale University and is the Founder and Principal of Health and Pharma Solutions LLC, a life sciences consulting firm advising organizations on drug development strategy.

Media Contact

Dr. Max Lataillade
Head of HIV Drug Development, Gates Foundation
max.lataillade@gatesfoundation.org

SOURCE: Dr. Max Lataillade